Literature DB >> 12482022

Calpain, calpastatin activities and ratios during myocardial ischemia-reperfusion.

D Enns1, M Karmazyn, J Mair, A Lercher, J Kountchev, A Belcastro.   

Abstract

The purpose of this study was to test the hypothesis that myocardial ischemia-reperfusion (I/R) is accompanied by an early burst in calpain activity, resulting in decreased calpastatin activity and an increased calpain/calpastatin ratio, thereby promoting increased protein release. To determine the possibility of a 'calpain burst' impacting cardiac calpastatin inhibitory activity, rat hearts were subjected (Langendorff) to either 45 or 60 min of ischemia followed by 30 min of reperfusion with and without pre-administration (s.c.) of a cysteine protease inhibitor (E-64c). Myocardial function, calpain activities (casein release assay), calpastatin inhibitory activity and release of CK, LDH, cTnI and cTnT were determined (n = 8 for all groups). No detectable changes in calpain activities were observed following I/R with and without E-64c (p > 0.05). Both I/R conditions reduced calpastatin activity (p < 0.05) while E-64c pre-treatment was without effect, implicating a non-proteolytic event underlying the calpastatin changes. A similar result was noted for calpain-calpastatin ratios and the release of all marker proteins (p < 0.05). In regard to cardiac function, E-64c resulted in transient improvements (15 min) for left ventricular developed pressure (LVDP) and rate of pressure development (p < 0.05). E-64c had no effect on end diastolic pressure (LVEDP) or coronary pressure (CP) during I/R. These findings demonstrate that restricting the putative early burst in calpain activity, suggested for I/R, by pre-treatment of rats with E-64c does not prevent downregulation of calpastatin inhibitory activity and/or protein release despite a transient improvement in cardiac function. It is concluded that increases in calpain isoform activities are not a primary feature of l/R changes, although the role of calpastatin downregulation remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482022     DOI: 10.1023/a:1020861120368

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Proteolysis of erythrocyte-type and brain-type ankyrins in rat heart after postischemic reperfusion.

Authors:  K Yoshida; K Harada
Journal:  J Biochem       Date:  1997-08       Impact factor: 3.387

2.  Quantitation of tissue calpain activity after isolation by hydrophobic chromatography.

Authors:  R Gopalakrishna; S H Barsky
Journal:  Anal Biochem       Date:  1985-08-01       Impact factor: 3.365

3.  MDL-28170, a membrane-permeant calpain inhibitor, attenuates stunning and PKC epsilon proteolysis in reperfused ferret hearts.

Authors:  F Urthaler; P E Wolkowicz; S B Digerness; K D Harris; A A Walker
Journal:  Cardiovasc Res       Date:  1997-07       Impact factor: 10.787

4.  Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart.

Authors:  H Iwamoto; T Miura; T Okamura; K Shirakawa; M Iwatate; S Kawamura; H Tatsuno; Y Ikeda; M Matsuzaki
Journal:  J Cardiovasc Pharmacol       Date:  1999-04       Impact factor: 3.105

5.  A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy.

Authors:  G D Arthur; A N Belcastro
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

6.  Human cardiac troponin I: precise identification of antigenic epitopes and prediction of secondary structure.

Authors:  G Ferrieres; C Calzolari; J C Mani; D Laune; S Trinquier; M Laprade; C Larue; B Pau; C Granier
Journal:  Clin Chem       Date:  1998-03       Impact factor: 8.327

7.  Downregulation of calpastatin in rat heart after brief ischemia and reperfusion.

Authors:  Y Sorimachi; K Harada; T C Saido; T Ono; S Kawashima; K Yoshida
Journal:  J Biochem       Date:  1997-10       Impact factor: 3.387

8.  Protective effect of the protease inhibitor leupeptin against myocardial stunning.

Authors:  Y Matsumura; H Kusuoka; M Inoue; M Hori; T Kamada
Journal:  J Cardiovasc Pharmacol       Date:  1993-07       Impact factor: 3.105

9.  Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion.

Authors:  K Yoshida; Y Yamasaki; S Kawashima
Journal:  Biochim Biophys Acta       Date:  1993-09-08

10.  Cardiomyocyte troponin T immunoreactivity is modified by cross-linking resulting from intracellular calcium overload.

Authors:  L Gorza; R Menabò; M Vitadello; C M Bergamini; F Di Lisa
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  4 in total

1.  Calpastatin domain L is a partial agonist of the calmodulin-binding site for channel activation in Cav1.2 Ca2+ channels.

Authors:  Etsuko Minobe; Hadhimulya Asmara; Zahangir A Saud; Masaki Kameyama
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle.

Authors:  Ashley J Smuder; Andreas N Kavazis; Kisuk Min; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2011-02-10

3.  Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload.

Authors:  Clifford R Greyson; Gregory G Schwartz; Li Lu; Shuyu Ye; Steve Helmke; Ya Xu; Hasan Ahmad
Journal:  J Mol Cell Cardiol       Date:  2007-10-23       Impact factor: 5.000

4.  Calpain/calpastatin activities and substrate depletion patterns during hindlimb unweighting and reweighting in skeletal muscle.

Authors:  Deborah L Enns; Truls Raastad; Ingrid Ugelstad; Angelo N Belcastro
Journal:  Eur J Appl Physiol       Date:  2007-04-12       Impact factor: 3.346

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.